GotchF.A., LevinN.W., PortF.K., WolfeR.A., UehlingerD.E.. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis1997; 30(1): 1–15.
10.
BashamL.M., AgarJ.W.M.. Time spent on dialysis; the paramount consideration in dialysis adequacy?Dial Transplant1997; 26: 739–49.
11.
CamusA.. The Myth of Sisyphus.Harmondsworth, England: Penguin Books Ltd1975; p 107–11.
12.
BerwickD.M.. Continuous improvement as an ideal in health care. N Eng J Med1989; 320(1): 53–6.
13.
AguayoR.. Dr Deming; the man who taught the Japanese about quality.London: Mercury Books; 1991; Chapter 5, Stable Systems p. 64–79.
14.
LeveyA.S., AdlerS., CaggiulaA.W.Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis1996; 27(5): 652–63.
15.
DolecekT.A., OlsonM.B., CaggiulaA.W.Registered dietitian time requirements in the Modification of Diet in Renal Disease Study. J Am Diet Assoc1995; 95(11): 1307–12.
16.
MyerlyS.H.. British Military Spectacle.Cambridge, Mass: Harvard University Press; 1996; Conclusion, The Martial Vision. p. 166–73.
17.
MinettiL.. Erythropoietin treatment in renal anaemia. How high should the target hematocrit be? J Nephrol1997; 10(3): 117–9.
18.
FishbaneS., TrenkleJ., MaesakaJ.K.. Utilizing continuous quality improvement techniques in dialysis: application to anemia management. Seminars in Dialysis1998; 11(1): 38–44.
19.
RosendaalF.R.. The Scylla and Charybdis of oral anticoagulant treatment. N Eng J Med1996; 335(8): 587–9.
20.
The European Atrial Fibrillation Trial Study Group.Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Eng J Med1995; 333(1): 5–10.
21.
CannegieterS.C., RosendaalF.R., WntzenA.R., van der MeerF.J., VandenbrouckeJ.P., BrietE.. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Eng J Med1995; 333(1): 11–7.
22.
HylekE.M., SkatesS.J., SheehanM.A., SingerD.E.. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Eng J Med1996; 335(8): 540–6.
23.
SmithW.C.S., LeeA.J., CrombieI.K., Tunstall-PedoeH.. Control of blood pressure in Scotland: the rule of halves. BMJ1990; 300: 981–3.
24.
SimonJ.A.. Treating hypertension: the evidence from clinical trials. BMJ1996; 313, 437–8.
25.
RitzE.. Hypertension and cardiac death in dialysis patients: should target blood pressure be lowered?Seminars in Dialysis1993; 6: 227–8.
26.
HanssonL.. The case for a greater blood pressure fall. Clinical & Experimental Hypertension1996; 18(3-4): 425–34.
27.
CruickshankJ.M., ThorpJ.M., ZachariasF.J.. Benefits and potential harm of lowering high blood pressure. Lancet1987; i: 581–4.
28.
MacMahonS., PetoR., CutlerJ.Blood pressure, stroke, and coronary disease. Part I, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet1990; 335: 765–74.
29.
OnrotJ.. Hypertension and the J-curve. How low should you go? Canadian Family Physician1993; 39: 1939–43.